Vistagen

Q2 2026 0.00%Q1 2026 +8.09%Q4 2025 -13.44%Q3 2025 +4.21%Q2 2025 +1.29%Q1 2025 -2.67%Q4 2024 +0.27%Q3 2024 +4.66%Q2 2024 -16.56%Q1 2024 -8.81%Q4 2023 +6.51%Q3 2023 -24.00%Q2 2023 +45.45%Q1 2023 -5.88%Q4 2022 -3.92%Q3 2022 -7.41%Q2 2022 +0.43%Q1 2022 +2.21%Q4 2021 +10.92%Q3 2021 -4.98%Q2 2021 +2.94%Q1 2021 -7.32%Q4 2020 +1.92%Q3 2020 -12.16%Q2 2020 +0.93%Q1 2020 -12.73%Q4 2019 -5.33%Q3 2019 -2.87%Q2 2019 -3.30%Q1 2019 -3.12%Q4 2018 +1.50%Q3 2018 +3.45%Q2 2018 -1.25%Q1 2018 0.00%Q4 2017 +2.19%Q3 2017 -10.18%Q2 2017 +2.37%Q1 2017 +6.27%Q4 2016 -9.87%Q3 2016 0.00%Q2 2016 0.00%Q1 2016 -9.21%Q4 2015 -6.25%Q3 2015 0.00%Q2 2015 0.00%Q1 2015 0.00%Q4 2014 -1.54%Q3 2014 0.00%Q2 2014 -8.57%Q1 2014 0.00%Q4 2013 0.00%Q3 2013 0.00%Q2 2013 0.00%Q1 2013 +94.12%Q4 2012 +94.12%Q3 2012 +1.82%Q2 2012 0.00%Q1 2012 0.00%Q4 2011 Q3 2011 Q2 2011 Q1 2011 Q4 2010

Feb 10, 2022

•

Dec 31, 2021

Vistagen Q3 2022 Earnings Report

Reported third quarter financial results and provided a corporate update.

Key Takeaways

VistaGen Therapeutics reported its third quarter results, reflecting progress in advancing novel therapies for mental health disorders. The company is anticipating Phase 3 data for studies in the PALISADE program for PH94B in social anxiety disorder later this year and expanding clinical programs to explore opportunities in additional mental health conditions.

Advanced late-stage PH94B clinical program, with progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials in social anxiety disorder expected in mid-2022 and second half 2022, respectively.

Initiated PALISADE Long-term Safety Study and exploratory Phase 2A trial in adjustment disorder with anxiety (AjDA).

Made preparations for clinical development in additional anxiety indications.

Phase 1B exploratory study for AV-101 in combination with probenecid is underway.